Another prospective longitudinal study developed in a tertiary care center in India that included 80 patients with type 2 diabetes who started the treatment with SGLT2 inhibitors aimed to evaluate the prevalence of genital and urinary tract infections at baseline and after 12 weeks from the initiation. Here, SLC5A2 is linked to urinary tract infection.